These Recent Insider Purchases Could Be Strong Signals To Potential Investors
When it comes to insider buying, the author of today’s article notes that “Conventional wisdom says that insiders and 10% owners really only buy shares…
When it comes to insider buying, the author of today’s article notes that “Conventional wisdom says that insiders and 10% owners really only buy shares…
A huge opportunity exists for a group of biotech stocks seeking to “hijack the immune system” with bispecific antibodies. Just what are bispecific antibodies –…
With a potential blockbuster drug in its pipeline that would also be the first new therapy for Alzheimer’s disease in decades, the stock featured in…
If stronger-than-expected fourth-quarter earnings, the prospect of massive government stimulus, and accelerating vaccine distribution has you feeling bullish, a perfect bet right now may be…
“The allure of penny stocks lies in their potential to deliver massive gains in a short period of time. But in exchange for that opportunity,…
“Few areas in equities are more volatile than small-cap biotech, biopharma and health care. Combined, these sectors produce more massive winners and horrid losers than…
This previously little-known immunotherapy stock recently saw its shares soar nearly 249% — and its market value surge from $300 million to more than $1…
When it comes to unicorns – privately held startup companies valued at $1 billion or more – the author of today’s article remarks that the…
After crashing in March as the novel coronavirus became a global crisis dramatically affecting everyday life, small-cap stocks have staged a remarkable rebound. And while…
Assessing the current state of the biotech industry, the author of today’s article notes that “While the coronavirus treatments will take center stage in 2021,…